Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Gorczyński, Adama; * | Miszewski, Kevinb | Gager, Yannc | Koch, Sonjad | Pötschke, Janed | Ugrinovski, Dimitard | Gabert, Jörgd | Pospieszyńska, Agatae | Wydra, Dariusze | Duchnowska, Renataf | Szymanowski, Bartoszf | Cierniak, Szczepang | Kruecken, Irened; h | Neumann, Karsteni | Mirkov, Katarinai | Biernat, Wojciecha | Czapiewski, Piotri
Affiliations: [a] Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland | [b] Department of Urology, Medical University of Gdansk, Gdansk, Poland | [c] ParoX GmbH, Leipzig, Germany | [d] PathoNext GmbH, Leipzig, Germany | [e] Department of Gynecology, Obstetrics and Neonatology, Medical University of Gdansk, Gdansk, Poland | [f] Department of Oncology, Military Institute of Medicine, National Research Institute, Warsaw, Poland | [g] Department of Pathology, Military Institute of Medicine, National Research Institute, Warsaw, Warsaw, Poland | [h] Institute of Pathology, University of Leipzig, Leipzig, Germany | [i] Institute of Pathology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany
Correspondence: [*] Corresponding author: Adam Gorczyński, Department of Pathomorphology, Medical University of Gdansk, Mariana Smoluchowskiego 17, 80-214 Gdansk, Poland. Tel.: + 48 698480519; E-mail: adam.gorczynski@gumed.edu.pl.
Abstract: BACKGROUND: ALK receptor tyrosine kinase (ALK) aberrations have an established role in pathogenesis of many neoplasms, but their clinical significance in high grade serous ovarian carcinoma (HGSOC) is unclear. OBJECTIVE: To analyse the frequency of ALK overexpression, molecular abnormalities of ALK, and their impact on the progression-free survival (PFS) and overall survival (OS) in HGSOC. METHODS: Protein expression was examined by immunohistochemistry (IHC) using three different clones of anti-ALK antibody. The presence of translocations was analysed using fluorescent in situ hybridization. Next-generation sequencing was used for studying the copy number variation, as well as point mutation and translocations involving other commonly rearranged genes. RESULTS: ALK overexpression was demonstrated in up to 52% of tumours, whereas ALK copy gains in 8.2%, with no clear impact on survival. ALK point mutations were identified in 13 tumours (8.9%), with 3 belonging to the class IV showing significantly better OS. A trend suggesting better PFS was also noticed in these cases. Additionally, three gene fusions were found: ERBB2-GRB7, PRKCA-BRCA1 and SND1-BRAF, none of which has been previously described in HGSOC. CONCLUSIONS: HGSOC harbouring activating ALK mutations might be associated with a better survival, while ALK overexpression and ALK amplification does not impact the prognosis.
Keywords: BRCA1, BRAF, ERBB2, fusion, point mutations
DOI: 10.3233/CBM-230117
Journal: Cancer Biomarkers, vol. 38, no. 1, pp. 17-26, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl